Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Jobs & workplace
Jin Ho Kang from UCLA and Alan Zhang from Quantum Design install the QPU (Quantum Processor Unit) onto a Proteox®S Dilution Refrigerator Landmark collaboration to promote quantum technologies in California This exciting partnership will advance SoCal Quantum Alliance (SQA) quantum computing ecosystem, accelerating scientific discovery, workforce development, and commercial applications.” — Dr. Stefano Spagna SAN DIEG
Oct 22 · 13:04·EIN Presswire
Medical devices
The Companion Diagnostics Market is covered by Business Market Insights with 2025 as the base year and 2026–2033 as the forecast period. The retrieved public source material for this batch did not expose all three headline values required for a ...
Read more
Oct 22 · 13:04·PR News Releaser
In the wire
8.3
Oct 22 · 13:03·GlobeNewswire
Healthcare · Education
TORONTO, ONTARIO - October 22, 2026 - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.
The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS.
The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release.
Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term.
SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs.
About NeuroThera Labs Inc.
NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
For further information, please contact:
Michal Efraty
IR Manager
NeuroThera Labs Inc.
Telephone: +972-3-7617108
Email: michal@efraty.com
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Notice on Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release.
Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca).
The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.
Oct 22 · 13:01·NewMediaWire
Energy · Sustainability
The global Biorefinery Market is gaining momentum as industries increasingly adopt renewable resources, low-carbon technologies, and sustainable production methods. The market was valued at US$ 61.33 billion in 2025 and is projected to reach US$ 133.75 billion by 2033, expanding ...
Read more
Oct 22 · 13:01·PR News Releaser
Finance · AI
Funding through the CHIPS Research and Development Office (CRDO) Will Advance Critical Technology That Unlocks Compute Power for U.S. AI Data Centers BOSTON, October 22, 2026--Vertical Semiconductor , a power semiconductor company, today announced it has signed a letter of intent with the U.S. Departm
Oct 22 · 13:01·Business Wire
Crypto · AI
New enterprise AI use cases and research findings show how organizations can move from AI experimentation to measurable value up to 24x faster while improving the economics of AI
Oct 22 · 13:00·Lenovo
SaaS
Lock in and load out this GFN Thursday. Call of Duty: Modern Warfare 4 arrives on GeForce NOW at launch, bringing a new campaign, multiplayer action and DMZ, high-stakes extraction mode to supported devices. The campaign also gets an enhanced look: GeForce RTX 5080-class performance arrives for Ultimate members, bringing support for ray-tracing features in […]
Oct 22 · 13:00·NVIDIA
Crypto
San Francisco, CA, 22nd October 2026, FinanceWire … Read More
The post Uphold Launches Automated, Data-Driven Trading Strategies for Everyday Crypto Investors appeared first on FinanceWire - Financial Press Release Distribution, Finance PR.
Oct 22 · 13:00·FinanceWire
Energy · Software & IT
By Oracle—Oct 22, 2026 Project Jupiter’s updated energy plan is designed to substantially reduce nitrogen oxide (NOx) emissions compared to previous plans, use a negligible amount of water , and allow the data center to generate power through a private microgrid. The campus will not require New Mexico utility customers to fund new generation, transmission, or distribution infrastructure for the project. New Mexico’s
Oct 22 · 13:00·Oracle
Healthcare
Research Advances in Embryo Genetics, Male-Factor Infertility and More to Improve Clinical Processes and Outcomes Across the Fertility Industry BASKING RIDGE, N.J., October 22, 2026--Everleap Fertility , a leader in fertility care and assisted reproduction, will deliver 19 scientific presentations at
Oct 22 · 13:00·Business Wire
Finance · Semiconductors
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company's financial results for its fourth quarter and fiscal 2026 on...
Oct 22 · 13:00·Qualcomm